Sequenom, Inc. (SQNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sequenom, Inc. (SQNM)

SQNM 2.390

0.0%

Sep 8 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Nav Toor who started this subject	10/17/2002 6:59:47 AM
From: nigel bates	of 364

SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM - News) today announced that it has sold two additional MassARRAY(TM) systems to GlaxoSmithKline. The additional sales follow an initial MassARRAY system purchase by GlaxoSmithKline earlier this year and a collaborative project between the two companies that generated a significant portion of SEQUENOM's genome-wide portfolio of validated SNP assays. The MassARRAY system is SEQUENOM's industry leading technology platform for high-performance analysis of genetic variation. "We are very pleased with the two additional MassARRAY system installations at GlaxoSmithKline following our initial placement less than four months ago," said Toni Schuh, Ph.D., SEQUENOM's President and Chief Executive Officer. "These systems are supported by the launch of our Allelotyping product for quantitative gene analysis, which complements our existing platform, software and consumable products. We are happy to see large pharmaceutical companies such as GlaxoSmithKline continuing to make a significant investment in our MassARRAY technology."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next